180 related articles for article (PubMed ID: 18248553)
1. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
[TBL] [Abstract][Full Text] [Related]
3. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
4. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
[TBL] [Abstract][Full Text] [Related]
5. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.
Wang J; Buchholz TA; Middleton LP; Allred DC; Tucker SL; Kuerer HM; Esteva FJ; Hortobagyi GN; Sahin AA
Cancer; 2002 Jun; 94(12):3107-14. PubMed ID: 12115341
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
8. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
9. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
12. Changes in tumour biological markers during primary systemic chemotherapy (PST).
Neubauer H; Gall C; Vogel U; Hornung R; Wallwiener D; Solomayer E; Fehm T
Anticancer Res; 2008; 28(3B):1797-804. PubMed ID: 18630463
[TBL] [Abstract][Full Text] [Related]
13. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
[TBL] [Abstract][Full Text] [Related]
14. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
Buchholz TA; Huang EH; Berry D; Pusztai L; Strom EA; McNeese MD; Perkins GH; Schechter NR; Kuerer HM; Buzdar AU; Valero V; Hunt KK; Hortobagyi GN; Sahin AA
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1337-42. PubMed ID: 15275718
[TBL] [Abstract][Full Text] [Related]
15. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
[TBL] [Abstract][Full Text] [Related]
16. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Taucher S; Rudas M; Mader RM; Gnant M; Sporn E; Dubsky P; Roka S; Bachleitner T; Fitzal F; Kandioler D; Wenzel C; Steger GG; Mittlböck M; Jakesz R
Breast Cancer Res Treat; 2003 Dec; 82(3):207-13. PubMed ID: 14703068
[TBL] [Abstract][Full Text] [Related]
17. [The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].
Wang S; Zhang JQ; Qiao XM; Yang DQ; Tong FZ; Liu HJ
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):1011-3. PubMed ID: 16194363
[TBL] [Abstract][Full Text] [Related]
18. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
Kasami M; Uematsu T; Honda M; Yabuzaki T; Sanuki J; Uchida Y; Sugimura H
Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
20. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?
Burge CN; Chang HR; Apple SK
Breast; 2006 Apr; 15(2):167-72. PubMed ID: 16095904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
